Cargando…

[(18)F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer’s disease

Cross-sectional studies have indicated potential for positron emission tomography (PET) in imaging tau pathology in Alzheimer’s disease (AD); however, its prognostic utility remains unproven. In a longitudinal, multi-modal, prognostic study of cognitive decline, 20 patients with a clinical biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiotis, Konstantinos, Savitcheva, Irina, Poulakis, Konstantinos, Saint-Aubert, Laure, Wall, Anders, Antoni, Gunnar, Nordberg, Agneta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758479/ https://www.ncbi.nlm.nih.gov/pubmed/32616831 http://dx.doi.org/10.1038/s41380-020-0815-4

Ejemplares similares

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
por: Chiotis, Konstantinos, et al.
Publicado: (2016)

Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease
por: Saint-Aubert, Laure, et al.
Publicado: (2016)

Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [(18)F]THK5317 PET
por: Jonasson, My, et al.
Publicado: (2019)

Assessment of Tau Pathology as Measured by (18)F-THK5317 and (18)F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
por: Colato, Elisa, et al.
Publicado: (2021)

In vivo imaging of tau deposition in Alzheimer’s disease using both [(18)F]-THK5317 and [(18)F]-S16: A pilot human study
por: Fu, Liping, et al.
Publicado: (2022)

Spatial Normalization of (18)F-Flutemetamol PET Images Using an Adaptive Principal-Component Template
por: Lilja, Johan, et al.
Publicado: (2019)

Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue
por: Lemoine, Laetitia, et al.
Publicado: (2015)

Clinical impact of [(18)F]flutemetamol PET among memory clinic patients with an unclear diagnosis
por: Leuzy, Antoine, et al.
Publicado: (2019)

Cortical laminar tau deposits and activated astrocytes in Alzheimer’s disease visualised by (3)H-THK5117 and (3)H-deprenyl autoradiography
por: Lemoine, Laetitia, et al.
Publicado: (2017)

Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
por: Bucci, Marco, et al.
Publicado: (2021)

Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging
por: Chiotis, Konstantinos, et al.
Publicado: (2015)

Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism
por: Smailovic, Una, et al.
Publicado: (2020)

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease
por: Rodriguez-Vieitez, Elena, et al.
Publicado: (2016)

Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain
por: Chiotis, Konstantinos, et al.
Publicado: (2018)

Tau PET imaging: present and future directions
por: Saint-Aubert, Laure, et al.
Publicado: (2017)

Comparison of subtyping methods for neuroimaging studies in Alzheimer’s disease: a call for harmonization
por: Mohanty, Rosaleena, et al.
Publicado: (2020)

Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
por: Lemoine, Laetitia, et al.
Publicado: (2017)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease
por: Carter, Stephen F., et al.
Publicado: (2018)

Clinical impact of (18)F-FDG-PET among memory clinic patients with uncertain diagnosis
por: Perini, Giulia, et al.
Publicado: (2020)

[(18)F]THK-5351 PET Patterns in Patients With Alzheimer’s Disease and Negative Amyloid PET Findings
por: Oh, Minyoung, et al.
Publicado: (2022)

Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic
por: Bucci, Marco, et al.
Publicado: (2023)

(18)F-THK5351 PET Imaging in the Behavioral Variant of Frontotemporal Dementia
por: Nam, Gijin, et al.
Publicado: (2018)

[(18)F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment
por: Jeong, Hye Jin, et al.
Publicado: (2020)

(18)F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies
por: Ezura, Michinori, et al.
Publicado: (2021)

Longitudinal Assessment of Tau Pathology in Patients with Alzheimer’s Disease Using [(18)F]THK-5117 Positron Emission Tomography
por: Ishiki, Aiko, et al.
Publicado: (2015)

Comparison of (18)F-T807 and (18)F-THK5117 PET in a Mouse Model of Tau Pathology
por: Brendel, Matthias, et al.
Publicado: (2018)

Neuroimaging-pathological correlations of [(18)F]THK5351 PET in progressive supranuclear palsy
por: Ishiki, Aiko, et al.
Publicado: (2018)

Distinct [(18)F]THK5351 binding patterns in primary progressive aphasia variants
por: Schaeverbeke, Jolien, et al.
Publicado: (2018)

(18)F–THK–5351, Fluorodeoxyglucose, and Florbetaben PET Images in Atypical Alzheimer’s Disease: A Pictorial Insight into Disease Pathophysiology
por: Park, Sohee, et al.
Publicado: (2021)

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
por: Chiotis, Konstantinos, et al.
Publicado: (2023)

Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding
por: Lemoine, Laetitia, et al.
Publicado: (2018)

Tau PET With (18)F-THK-5351 Taiwan Patients With Familial Alzheimer's Disease With the APP p.D678H Mutation
por: Huang, Chin-Chang, et al.
Publicado: (2019)

Gray matter structural networks related to (18)F-THK5351 retention in cognitively normal older adults and Alzheimer's disease patients
por: Shigemoto, Yoko, et al.
Publicado: (2021)

Visualization of ischemic stroke-related changes on (18)F-THK-5351 positron emission tomography
por: Huang, Kuo-Lun, et al.
Publicado: (2018)

[(18)F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy
por: Brendel, Matthias, et al.
Publicado: (2018)

(18)F-THK5351 PET Imaging in Nonfluent-Agrammatic Variant Primary Progressive Aphasia
por: Yoon, Cindy W, et al.
Publicado: (2018)

Relationships between [(18)F]-THK5351 Retention and Language Functions in Primary Progressive Aphasia
por: Jeong, Hye Jin, et al.
Publicado: (2019)

Early brainstem ([18F])THK5351 uptake is linked to cortical hyperexcitability in healthy aging
por: Van Egroo, Maxime, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f7s5o67lc2c16rmhohlad6p9i8